A novel phytomedicine for treatment and management of oral submucous fibrosis
A phytomedicine using carvone, eugenol, and cinnamaldehyde in diverse formulations effectively treats and manages oral submucous fibrosis, offering a permanent cure and anti-inflammatory benefits while preventing further damage and cancer risk.
Patent Information
- Application Number
- PCT/IN2026/050765
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-04
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for oral submucous fibrosis are ineffective, irreversible, provide short-term relief, are costly, and have potential side effects, failing to address the condition's progression and malignant potential.
A phytomedicine comprising carvone, eugenol, and cinnamaldehyde in various dosage forms such as oral rinse, thin film, therapeutic mouth gel, medicated chewing gum, and medicated gummies, sourced from specific plant families, offering anti-inflammatory effects to manage and cure oral submucous fibrosis.
Provides a long-lasting, permanent cure for oral submucous fibrosis, restores buccal mucosa elasticity, prevents further mucosal damage, and reduces the risk of oral cancer without side effects or habit formation.
Smart Images

Figure IN2026050765_12112026_PF_FP_ABST
Abstract
Description
[0001] A NOVEL PHYTOMEDICINE FOR TREATMENT AND MANAGEMENT OF ORAL SUBMUCOUS FIBROSIS FIELD OF INVENTION
[0002] The present invention relates to a novel phytomedicine. More specifically the present invention relates to a novel phytomedicine for the management and treatment of oral submucous fibrosis.
[0003] BACKGROUND OF INVENTION
[0004] Oral submucous fibrosis (OSMF) is a chronic disease of the oral cavity characterized by inflammation and progressive fibrosis of the submucosal tissues. Oral submucous fibrosis results in marked rigidity and an eventual inability to open the mouth. The buccal mucosa is the most commonly involved site, but any part of the oral cavity can be involved, even the pharynx. The condition is well recognized for its malignant potential and is particularly associated with areca nut chewing, the main component of betel quid. Oral dysplasia and squamous cell carcinomas are complications of oral submucous fibrosis.
[0005] In patients with oral submucous fibrosis, the risk of developing oral carcinoma is 7.6% over a 10-year period. If the palatal and paratubal muscles are involved in patients with oral submucous fibrosis, conductive hearing loss may occur due to functional stenosis of the eustachian tube. Other symptoms of oral submucous fibrosis include progressive inability to open the mouth (trismus) due to oral fibrosis and scarring, dryness of the mouth, impaired mouth movement, increased salivation and change of gustatory sensation.
[0006] Patients with oral submucous fibrosis who require anaesthesia for trismus correction and oncoplastic surgery may have difficulty during laryngoscopy and intubation of the trachea. No treatment is effective in patients with oral submucous fibrosis, and the condition remains irreversible. Reports claim improvement of the condition if the habit is discontinued following diagnosis at an early stage.WO2017117774A1 discloses the use of butylene benzoquinone to prevent and treat oral submucous fibrosis. The use of an active ingredient for the manufacture of a medicament, wherein the active ingredient is selected from the group consisting of butylidenephthalide (BP), a pharmaceutically acceptable salt.
[0007] JP5001484B2 discloses a Japanese patent for a chewing gum that contains curcumin to treat leukoplakia and submucosal fibrosis.
[0008] The limitations of existing invention include short term relief, slow results, high cost, limited effectiveness, pain, the need for medical supervision and potential side effects. The existing inventions are not effective for the treatment of oral submucous fibrosis and the condition remains irreversible. Thus, there is a need for the present invention to overcome the above discussed problem.
[0009] OBJECTIVE OF INVENTION
[0010] The main objective of the present invention is to provide effective, long lasting and permanent cure of oral sub mucous fibrosis.
[0011] Yet another objective of the present invention is to provide a cure for locked jaws and inelasticity of buccal mucosa.
[0012] Yet another objective of the present invention is to provide an oral rinse, an oral thin film, a therapeutic mouth gel, a medicated chewing gum and a medicated gummies as dosage for medication.
[0013] Yet another objective of the present invention is to prevent or inhibit further mucosal damage due to anti-inflammatory effect.
[0014] Yet another objective of the present invention is to ensure that it has no side effects and is not habit forming.
[0015] SUMMARY OF THE INVENTION
[0016] The present invention relates to a novel phytomedicine for treatment and management of Oral Submucous Fibrosis. The present invention includes a carvone, a eugenol, a cinnamaldehyde, an oral rinse, an oral thin film, a therapeuticmouth gel, a medicated chewing gum and a medicated gummies. The novel phytomedicine includes a active pharmaceutical ingredients including a carvone, a eugenol and a cinnamaldehyde together with a pharmaceutically acceptable carrier, diluent and / or excipients. The novel phytomedicine is available in plurality of dosage form including an oral rinse, an oral thin film, a therapeutic mouth gel, a medicated chewing gum and a medicated gummies, the oral rinse has type 1 and type 2 compositions. The active ingredient, the carvone is sourced from essential oil derived from species of Lamiaceae family plant, the eugenol and the cinnamaldehyde is sourced from essential oil of Lauraceae family plant. The composition of the Oral rinse type 1 includes: Carvone- 05% to 60% w / w, Eugenol and Cinnamaldehyde- 05% to 60% w / w, Surfactant- 03% to 08% w / w, Sweetener-02% to 08% w / w. The composition of the Oral rinse type 2 includes: Carvone -05% to 10% w / w, Eugenol and Cinnamaldehyde - 05% to 10% w / w, Solvents- QS to make 100%, Surfactant- 05% to 10% w / w, Preservatives- 01% to 05% w / w, Sweetener- 02% to 10% w / w. The composition of the oral thin film includes: Carvone - 10% to 50% w / w, Eugenol and Cinnamaldehyde - 10% to 50% w / w, Solvents- 05% to 10% w / w, Emulsifier- 03% to 10% w / w, Polymer- 01% to 05 % w / w, Plasticizer- 05% to 15% w / w. The composition of the therapeutic mouth gel includes: Carvone - 05% to 40% w / w, Eugenol and Cinnamaldehyde- 05% to 40% w / w, Hydroxypropyl methylcellulose (HPMC K14)- 03% to 10% w / w, polyethylene glycol -400400- 05% to 20% w / w, Sucrose- 01% to 05% w / w, Sodium Citrate- 0.05% to 0.1% w / w, Citric Acid- 0.2% to 0.5% w / w, Methyl Paraben- 02% to 0.5% w / w and Water. The composition of the medicated chewing gum includes: Carvone- 02% to 20% w / w, Eugenol and Cinnamaldehyde- 02% to 20% w / w, Sweetener- 0.02%- 8% w / w, Softener- 0.5%- 15% w / w, Emulsifier- 15%- 45% w / w, Antioxidant- 0.02%-0.05% w / w, Anti caking agent- 0.5%- 2% w / w, Colorant-0.1%- 0.5% w / w, Elastomer- 15%- 45% w / w, Elastomeric plasticizer- 5%- 15% w / w, Filler / Texturiser- QS to makel00%. The composition of the medicated gummies includes: Carvone- 5% to 20% w / w, Eugenol and Cinnamaldehyde- 05% to 20% w / w, Sucrose- 22% to 55% w / w, Agar- Agar- 05% to 10% w / w, Sorbitol-10% to 25% w / w, Sodium benzoate- 02% to 05% w / w, Beetroot extract- 05% to 10% w / w.
[0017] The main advantage of the present invention is that the present invention provides long lasting and permanent cure of oral sub mucous fibrosis.
[0018] Yet another advantage of the present invention is that the present invention provides the cure for locked jaws and brings back the elasticity of buccal mucosa.
[0019] Yet another advantage of the present invention is that the present invention provides oral rinse, oral thin film, therapeutic mouth gel, medicated chewing gum and medicated gummies as dosage for medication.
[0020] Yet another advantage of the present invention is that the present invention prevents or inhibit further mucosal damage due to anti-inflammatory effect and indirectly closes down the possibility of potential oral cancer.
[0021] Yet another advantage of the present invention is that the present invention has no side effects and no habit forming.
[0022] Further objectives, advantages, and features of the present invention will become apparent from the detailed description provided herein below, in which various embodiments of the disclosed invention are illustrated by way of example.
[0023] BRIEF DESCRIPTION OF THE DRAWINGS
[0024] The accompanying drawings are incorporated in and constitute a part of this specification to provide a further understanding of the invention. The drawings illustrate one embodiment of the invention and together with the description, serve to explain the principles of the invention.
[0025] Fig 1. illustrates the process of formation of oral thin film.
[0026] DETAILED DESCRIPTION OF THE INVENTION
[0027] DefinitionThe terms “a” or “an”, as used herein, are defined as one or as more than one. The term “plurality”, as used herein, is defined as two as or more than two. The term “another”, as used herein, is defined as at least a second or more. The terms “including” and / or “having”, as used herein, are defined as comprising (i.e., open language). The term “coupled”, as used herein, is defined as connected, although not necessarily directly, and not necessarily mechanically.
[0028] The term “comprising” is not intended to limit inventions to only claiming the present invention with such comprising language. Any invention using the term comprising could be separated into one or more claims using “consisting” or “consisting of’ claim language and is so intended. The term “comprising” is used interchangeably used by the terms “having” or “containing”.
[0029] Reference throughout this document to “one embodiment”, “certain embodiments”, “an embodiment”, “another embodiment”, and “yet another embodiment” or similar terms means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the appearances of such phrases or in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics are combined in any suitable manner in one or more embodiments without limitation. The term “or” as used herein is to be interpreted as an inclusive or meaning any one or any combination. Therefore, “A, B or C” means any of the following: “A; B; C; A and B; A and C; B and C; A, B and C”. An exception to this definition will occur only when a combination of elements, functions, steps, or acts are in some way inherently mutually exclusive.
[0030] As used herein, the term "one or more" generally refers to, but not limited to, singular as well as the plural form of the term.
[0031] The drawings featured in the figures are to illustrate certain convenient embodiments of the present invention and are not to be considered as a limitation to that. Term "means" preceding a present participle of operation indicates thedesired function for which there is one or more embodiments, i.e., one or more methods, devices, or apparatuses for achieving the desired function and that one skilled in the art could select from these or their equivalent in view of the disclosure herein and use of the term "means" is not intended to be limiting disclosure herein and use of the term "means" is not intended to be limiting.
[0032] Fig 1 illustrates the process of formation of oral thin film (100). The process included the dissolution of the polymer (104) and plasticizer (102) in a volatile solvent (106), like ethanol, acetone, water or a combination of solvents. Carvone, eugenol and cinnamaldehyde were added and suspended in the solution. The prepared polymeric solution (108) casted into a mold (110) and left for drying in hot air oven (112). Then the prepared thin films were peeled, cut and packed (114). The present invention relates to a novel phytomedicine for treatment and management of Oral Submucous Fibrosis. The present invention includes a carvone, a eugenol, a cinnamaldehyde, an oral rinse, an oral thin film, a therapeutic mouth gel, a medicated chewing gum and a medicated gummies. In an embodiment, the novel phytomedicine includes an active pharmaceutical ingredients including a carvone, a eugenol and a cinnamaldehyde together with a pharmaceutically acceptable carrier, diluent and / or excipients. In an embodiment, the novel phytomedicine has plurality of dosage form including an oral rinse, an oral thin film, a therapeutic mouth gel, a medicated chewing gum and a medicated gummies, the oral rinse has type 1 and type 2 compositions. In an embodiment, the active ingredient, the carvone is sourced from essential oil derived from species of Lamiaceae family plant, the eugenol and the cinnamaldehyde is sourced from essential oil of Lauraceae family plant, the properties of carvone include: Class: monoterpene ketone, Formula: Cl OH 140, Molar mass: 150.22 g / mol, Density: 960 kg / m3, Boiling point: 231 °C, Melting point: 25.2 °C, Classification: Terpenoid. The properties of eugenol include: Class: allylbenzene, Chemical formula: C10H12O2, Molar mass: 164.204 g mol-1, Density: 1.06 g / cm3, Melting point: -7.5 °C (18.5 °F; 265.6 K), Boiling point: 254 °C (489 °F; 527 K), Acidity (pKa): 10.19 at 25 °C. The properties of cinnamaldehyde include:Class: phenylpropanoid (flavonoid), Chemical formula: C9H8O, Molar mass: 132.16 g / mol, Density: 1.0497 g / mL, Melting point: -7.5 °C (18.5 °F; 265.6 K), Boiling point: 248 °C (478 °F; 521 K), Refractive index (nD): 1.6195.
[0033] In an embodiment, the composition of the oral rinse type 1 includes: Carvone- 05% to 60% w / w, Eugenol and Cinnamaldehyde- 05% to 60% w / w, Surfactant- 03% to 08% w / w, Sweetener- 02% to 08% w / w. In an embodiment, the composition of the oral rinse type 2 includes: Carvone - 05% to 10% w / w, Eugenol and Cinnamaldehyde - 05% to 10% w / w, Solvents- QS to make 100%, Surfactant- 05% to 10% w / w, Preservatives- 01% to 05% w / w, Sweetener- 02% to 10% w / w.
[0034] In an embodiment, the composition of the oral thin film includes: Carvone - 10% to 50% w / w, Eugenol and Cinnamaldehyde - 10% to 50% w / w, Solvents- 05% to 10% w / w, Emulsifier- 03% to 10% w / w, Polymer- 01% to 05 % w / w, Plasticizer-05% to 15% w / w.
[0035] In an embodiment, the composition of the therapeutic mouth gel includes: Carvone - 05% to 40% w / w, Eugenol and Cinnamaldehyde- 05% to 40% w / w, Hydroxypropyl methylcellulose (HPMC K14)- 03% to 10% w / w, polyethylene gly col-400 400- 05% to 20% w / w, Sucrose- 01% to 05% w / w, Sodium Citrate-0.05% to 0.1% w / w, Citric Acid- 0.2% to 0.5% w / w, Methyl Paraben- 02% to 0.5% w / w and Water.
[0036] In an embodiment, the composition of the medicated chewing gum includes: Carvone- 02% to 20% w / w, Eugenol and Cinnamaldehyde- 02% to 20% w / w, Sweetener- 0.02%- 8% w / w, Softener- 0.5%- 15% w / w, Emulsifier- 15%- 45% w / w, Antioxidant- 0.02%-0.05% w / w, Anti caking agent- 0.5%- 2% w / w, Colorant-0.1%- 0.5% w / w, Elastomer- 15%- 45% w / w, Elastomeric plasticizer- 5%- 15% w / w, Filler / Texturiser- QS to makel00%.
[0037] In an embodiment, the composition of the medicated gummies includes: Carvone-5% to 20% w / w, Eugenol and Cinnamaldehyde- 05% to 20% w / w, Sucrose- 22% to 55% w / w, Agar- Agar- 05% to 10% w / w, Sorbitol- 10% to 25% w / w, Sodium benzoate- 02% to 05% w / w, Beetroot extract- 05% to 10% w / w.In an embodiment, a method for preparation of the composition of the novel phytomedicine for the treatment and management of Oral Submucous Fibrosis includes:
[0038] Oral rinse typel
[0039] Mixed the carvone, eugenol, cinnamaldehyde and stirred thoroughly,
[0040] Add the surfactant to the mixture and mixed thoroughly,
[0041] Add the sweetener and mix until the homogenous solution is obtained,
[0042] pH of the solution is adjusted to ensure stability and efficacy by using buffers like citric acid or sodium citrate,
[0043] viscosity of the solution is adjusted to ensure ease of use and to prevent separation or excessive thickening, and
[0044] final product is evaluated for stability, clarity and other quality parameters.
[0045] Oral rinse type 2
[0046] PHASE 1: Carvone, eugenol, cinnamaldehyde are combined with surfactant, ensuring they are fully dissolved or dispersed,
[0047] PHASE 2: preservatives and sweeteners are added to water and mixed thoroughly, Phase 1 is added to Phase 2 slowly while giving continuous stirring till homogenise solution is obtained,
[0048] pH of the solution is adjusted to ensure stability and efficacy by using buffers like citric acid or sodium citrate,
[0049] viscosity of the solution is adjusted to ensure ease of use and to prevent separation or excessive thickening, and final product is evaluated for stability, clarity, and other quality parameters.
[0050] Oral thin filmthe process of formation of oral thin film (100), the process includes the dissolution of the polymer (104) and plasticizer (102) in a volatile solvent (106), like ethanol, acetone, water or a combination of solvents,
[0051] carvone, eugenol and cinnamaldehyde were added and suspended in the solution, the prepared polymeric solution (108) casted into a mold (110) and left for drying in hot air oven (112),
[0052] then the prepared thin films were peeled, cut and packed (114).
[0053] Therapeutic mouth gel
[0054] ingredients for formulation of the gel were properly weighed, hydroxypropyl methylcellulose (HPMC K14) was dispersed in water maintained at 70°C for 20 minutes using a magnetic stirrer,
[0055] polyethylene glycol-400, sucrose, citric acid and preservatives were added with continuous stirring,
[0056] required amount of sodium citrate was dissolved in water and added to mixture, carvone, eugenol, cinnamaldehyde were added slowly while mixing and speed was maintained appropriately, and
[0057] mixture was allowed to cool to room temperature to form gel.
[0058] Medicated chewing gum
[0059] process for manufacturing chewing gum is to melt and soften the gum base at about 60°C and place it in a kettle mixer to soften the base, then other ingredients such as sugar, glycerine, sweeteners, taste-masking agent are added to softened base, lately the flavouring agent is added in the mixing procedure at 40°C, then cooling and rolling steps would be done, and the rolled chewing gum would then be cut into pieces of desired shapes and sizes. To make a coated gum tablet, a coating agent should be sprayed to form a uniform surface.
[0060] Medicated gummiesthe method of gummy preparation includes preparation of two solutions, i.e., a solution of water and sugar and a solution of agar and water,
[0061] add sucrose in water then heat the solution on medium high while being stirred, adjust the temperature to a point where the temperature of the solution doesn’t rise above 130°C,
[0062] keep heating until viscous sugar syrup is formed, avoid overheating to prevent the caramelization of sugars,
[0063] once a thick, consistent syrup is obtained, turn off the flam, lower its temperature to 60°C,
[0064] mix agar in water in another vessel and heated for a few minutes on low heat, pour the agar into the warm sugar solution & mix thoroughly, & than heat the mixture for a few seconds to 70°C,
[0065] add the carvone, eugenol, cinnamaldehyde to the above mixture and stir to form uniform solution, lately add Sorbitol, Beetroot extract and Na benzoate to the solution & mix it thoroughly,
[0066] lubricant the silicon mould with glycerine to avoid sticking, pour the warm mixture into the mould & tap them on the shelf to even up the level of fillings, remove and wipe any excess solution from the mould, and
[0067] place the mould in a safe place at room temperature for 60 mins.
[0068] In a preferred embodiment, the novel phytomedicine intends to bring back the elasticity of buccal mucosa, opened up locked jaws and indirectly closes down the possibility of potential oral cancer.
Claims
I / WE Claim1. A novel phytomedicine for treatment and management of Oral Submucous Fibrosis, the novel phytomedicine comprising:An active pharmaceutical ingredients including a carvone, a eugenol and a cinnamaldehyde together with a pharmaceutically acceptable carrier, diluent and / or excipients;characterized in that, the novel phytomedicine has plurality of dosage form including an oral rinse, an oral thin film, a therapeutic mouth gel, a medicated chewing gum and a medicated gummies, wherein the oral rinse has type 1 and type 2 compositions.
2. The active pharmaceutical ingredients as claimed in claim 1, wherein the carvone is sourced from essential oil derived from species of Lamiaceae family plant, the eugenol and the cinnamaldehyde is sourced from essential oil of Lauraceae family plant, wherein properties comprising:CarvoneClass: monoterpene ketoneFormula: C10H14OMolar mass: 150.22 g / molDensity: 960 kg / m3Boiling point: 231 °CMelting point: 25.2 °CClassification: TerpenoidEugenolClass: allylbenzeneChemical formula: C10H12O2Molar mass: 164.204 g mol-1Density: 1.06 g / cm3Melting point: -7.5 °C (18.5 °F; 265.6 K)Boiling point: 254 °C (489 °F; 527 K)Acidity (pKa): 10.19 at 25 °CCinnamaldehydeClass: phenylpropanoid (flavonoid)Chemical formula: C9H8OMolar mass: 132.16 g / molDensity: 1.0497 g / mLMelting point: -7.5 °C (18.5 °F; 265.6 K)Boiling point: 248 °C (478 °F; 521 K)Refractive index (nD): 1.61953. The oral rinse as claimed in claim 1, wherein the composition of the oral rinse comprising:Oral rinse type 1Carvone- 05% to 60% w / wEugenol and Cinnamaldehyde- 05% to 60% w / wSurfactant- 03% to 08% w / wSweetener- 02% to 08% w / wOral rinse type 2Carvone - 05% to 10% w / wEugenol and Cinnamaldehyde - 05% to 10% w / wSolvents- QS to make 100%Surfactant- 05% to 10% w / wPreservatives- 01% to 05% w / wSweetener- 02% to 10% w / w4. The oral thin film as claimed in claim 1, wherein the composition of the oral thin film comprising:Carvone - 10% to 50% w / wEugenol and Cinnamaldehyde - 10% to 50% w / wSolvents- 05% to 10% w / wEmulsifier- 03% to 10% w / wPolymer- 01% to 05 % w / wPlasticizer- 05% to 15% w / w5. The therapeutic mouth gel as claimed in claim 1, wherein the composition of the therapeutic mouth gel comprising:Carvone - 05% to 40% w / wEugenol and Cinnamaldehyde- 05% to 40% w / wHydroxypropyl methylcellulose (HPMC KI 4)- 03% to 10% w / w polyethylene glycol-400400- 05% to 20% w / wSucrose- 01% to 05% w / wSodium Citrate- 0.05% to 0.1% w / wCitric Acid- 0.2% to 0.5% w / wMethyl Paraben- 02% to 0.5% w / wWater6. The medicated chewing gum as claimed in claim 1, wherein the composition of the medicated chewing gum comprising:Carvone- 02%- 20% w / wEugenol and Cinnamaldehyde- 02%- 20% w / wSweetener- 0.02%- 8% w / wSoftener- 0.5%- 15% w / wEmulsifier- 15%- 45% w / wAntioxidant- 0.02%- 0.05% w / wAnti caking agent- 0.5%- 2% w / wColorant- 0.1%- 0.5% w / wElastomer- 15%- 45% w / wElastomeric plasticizer- 5%- 15% w / wFiller / Texturiser- QS to makel00%7. The medicated gummies as claimed in claim 1, wherein the composition of the medicated gummies comprising:Carvone- 5% to 20% w / wEugenol and Cinnamaldehyde- 05% to 20% w / wSucrose- 22% to 55% w / wAgar- Agar- 05% to 10% w / wSorbitol- 10% to 25% w / wSodium benzoate- 02% to 05% w / wBeetroot extract- 05% to 10% w / wA method for the preparation of the composition of the novel phytomedicine for the treatment and management of Oral Submucous Fibrosis, wherein the method comprises:Oral rinse type 1Mixed the carvone, eugenol, cinnamaldehyde and stirred thoroughly,Add the surfactant to the mixture and mixed thoroughly,Add the sweetener and mix until the homogenous solution is obtained,pH of the solution is adjusted to ensure stability and efficacy by using buffers like citric acid or sodium citrate,viscosity of the solution is adjusted to ensure ease of use and to prevent separation or excessive thickening, andfinal product is evaluated for stability, clarity and other quality parameters.Oral rinse type 2PHASE 1: Carvone, eugenol, cinnamaldehyde are combined with surfactant, ensuring fully dissolution or dispersion,PHASE 2: preservatives and sweeteners are added to water and mixed thoroughly, Phase 1 is added to Phase 2 slowly while giving continuous stirring till homogenise solution is obtained,pH of the solution is adjusted to ensure stability and efficacy by using buffers like citric acid or sodium citrate,viscosity of the solution is adjusted to ensure ease of use and to prevent separation or excessive thickening, andfinal product is evaluated for stability, clarity, and other quality parameters.Oral thin filmthe process of formation of oral thin film (100), the process includes the dissolution of the polymer (104) and plasticizer (102) in a volatile solvent (106), like ethanol, acetone, water or a combination of solvents,carvone, eugenol and cinnamaldehyde were added and suspended in the solution, the prepared polymeric solution (108) casted into a mold (110) and left for drying in hot air oven (112),then the prepared thin films were peeled, cut and packed (114).Therapeutic mouth gelingredients for formulation of the gel were properly weighed, hydroxypropyl methylcellulose (HPMC K14) was dispersed in water maintained at 70°C for 20 minutes using a magnetic stirrer,polyethylene glycol-400, sucrose, citric acid and preservatives were added with continuous stirring,required amount of sodium citrate was dissolved in water and added to mixture, carvone, eugenol, cinnamaldehyde were added slowly while mixing and speed was maintained appropriately, andmixture was allowed to cool down at room temperature to form gel.Medicated chewing gumprocess for manufacturing chewing gum is to melt and soften the gum base at about 60°C and place it in a kettle mixer to soften the base, then other ingredients such as sugar, glycerine, sweeteners, taste-masking agent are added to softened base, lately the flavouring agent is added in the mixing procedure at 40°C, then cooling and rolling steps would be done, and the rolled chewing gum would then be cut into pieces of desired shapes and sizes. To make a coated gum tablet, a coating agent should be sprayed to form a uniform surface.Medicated gummiesthe method of gummy preparation includes preparation of two solutions, i.e., a solution of water and sugar and a solution of agar and water,add sucrose in water then heat the solution on medium high while being stirred, adjust the temperature to a point where the temperature of the solution doesn’t rise above 130°C,keep heating until viscous sugar syrup is formed, avoid overheating to prevent the caramelization of sugars,once a thick, consistent syrup is obtained, turn off the flame, lower its temperature to 60°C,mixed the agar in water in another vessel and heated for a few minutes on low heat, pour the agar into the warm sugar solution & mix thoroughly, & than heat the mixture for a few seconds to 70°C,add carvone, eugenol, cinnamaldehyde to the above mixture and stir to form uniform solution, lately add Sorbitol, Beetroot extract and Na benzoate to the solution & mix it thoroughly,lubricant the silicon mould with glycerine to avoid sticking, poured the warm mixture into the mould & tap them on the shelf to even up the level of fillings, remove and wipe any excess solution from the mould, andplace the mould in a safe place at room temperature for 60 mins.
9. The novel phytomedicine as claimed in claim 1, wherein the novel phytomedicine intends to bring back the elasticity of buccal mucosa, opened up locked jaws and indirectly closes down the possibility of potential oral cancer.
